UBS Maintains Buy on Chemours, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Joshua Spector maintains a Buy rating on Chemours (NYSE:CC) but lowers the price target from $30 to $28.

August 06, 2024 | 3:34 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
UBS analyst Joshua Spector maintains a Buy rating on Chemours but lowers the price target from $30 to $28.
The Buy rating suggests continued confidence in Chemours' performance, but the lowered price target indicates some caution about its short-term prospects. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100